Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

Similar articles for PubMed (Select 20574155)

1.

VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells.

Ringer L, Sirajuddin P, Yenugonda VM, Ghosh A, Divito K, Trabosh V, Patel Y, Brophy A, Grindrod S, Lisanti MP, Rosenthal D, Brown ML, Avantaggiati ML, Rodriguez O, Albanese C.

Cancer Biol Ther. 2010 Aug 15;10(4):320-5. Epub 2010 Aug 3.

2.

VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells.

Ringer L, Sirajuddin P, Heckler M, Ghosh A, Suprynowicz F, Yenugonda VM, Brown ML, Toretsky JA, Uren A, Lee Y, MacDonald TJ, Rodriguez O, Glazer RI, Schlegel R, Albanese C.

Cancer Biol Ther. 2011 Nov 1;12(9):818-26. doi: 10.4161/cbt.12.9.17682. Epub 2011 Nov 1.

4.
5.

Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells.

Li H, Qi Y, Li C, Braseth LN, Gao Y, Shabashvili AE, Katovich MJ, Sumners C.

Mol Cancer Ther. 2009 Dec;8(12):3255-65. doi: 10.1158/1535-7163.MCT-09-0237. Epub .

7.

Inhibition of human prostate cancer cells proliferation by a selective alpha1-adrenoceptor antagonist labedipinedilol-A involves cell cycle arrest and apoptosis.

Liou SF, Lin HH, Liang JC, Chen IJ, Yeh JL.

Toxicology. 2009 Feb 4;256(1-2):13-24. doi: 10.1016/j.tox.2008.10.025. Epub 2008 Nov 14.

PMID:
19056458
8.
10.

New therapies for prostate cancer?

Tanowitz HB, Machado FS.

Cancer Biol Ther. 2010 Aug 15;10(4):326-8. doi: 10.4161/cbt.10.4.13102. Epub 2010 Aug 21. No abstract available.

11.

A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo.

Bemis DL, Capodice JL, Desai M, Buttyan R, Katz AE.

Clin Cancer Res. 2004 Aug 1;10(15):5282-92.

12.
13.

CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells.

Arisan ED, Obakan P, Coker-Gurkan A, Calcabrini A, Agostinelli E, Unsal NP.

Curr Pharm Des. 2014;20(2):180-8.

PMID:
23701543
14.
15.

A novel synthetic protoapigenone analogue, WYC02-9, induces DNA damage and apoptosis in DU145 prostate cancer cells through generation of reactive oxygen species.

Chen HM, Chang FR, Hsieh YC, Cheng YJ, Hsieh KC, Tsai LM, Lin AS, Wu YC, Yuan SS.

Free Radic Biol Med. 2011 May 1;50(9):1151-62. doi: 10.1016/j.freeradbiomed.2011.01.015. Epub 2011 Jan 20.

PMID:
21256211
16.

Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades.

Kim SM, Park JH, Kim KD, Nam D, Shim BS, Kim SH, Ahn KS, Choi SH, Ahn KS.

Phytother Res. 2014 Mar;28(3):423-31. doi: 10.1002/ptr.5010. Epub 2013 May 20.

PMID:
23686889
17.
18.

Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI.

Sirajuddin P, Das S, Ringer L, Rodriguez OC, Sivakumar A, Lee YC, Üren A, Fricke ST, Rood B, Ozcan A, Wang SS, Karam S, Yenugonda V, Salinas P, Petricoin E 3rd, Pishvaian M, Lisanti MP, Wang Y, Schlegel R, Moasser B, Albanese C.

Cell Cycle. 2012 Oct 15;11(20):3801-9. doi: 10.4161/cc.21988. Epub 2012 Sep 14.

19.

Protoapigenone, a novel flavonoid, induces apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase 1/2.

Chang HL, Wu YC, Su JH, Yeh YT, Yuan SS.

J Pharmacol Exp Ther. 2008 Jun;325(3):841-9. doi: 10.1124/jpet.107.135442. Epub 2008 Mar 12.

20.

p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells.

Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas Mdel C, Olive M, Hsieh JT, Logothetis CJ, Navone NM.

Carcinogenesis. 2002 Aug;23(8):1289-96.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk